250 related articles for article (PubMed ID: 7621513)
1. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligodeoxynucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems.
Nicot A; Pfaff DW
J Neurosci Methods; 1997 Jan; 71(1):45-53. PubMed ID: 9125374
[TBL] [Abstract][Full Text] [Related]
3. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.
Peng Ho S; Livanov V; Zhang W; Li J; Lesher T
Brain Res Mol Brain Res; 1998 Nov; 62(1):1-11. PubMed ID: 9795101
[TBL] [Abstract][Full Text] [Related]
4. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
5. An overview of progress in antisense therapeutics.
Crooke ST
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
[No Abstract] [Full Text] [Related]
6. Pharmacology of therapeutic oligonucleotides.
Diasio RB; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
[No Abstract] [Full Text] [Related]
7. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
9. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
11. Antisense strategies: functions and applications in immunology.
Varga LV; Tóth S; Novák I; Falus A
Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355
[TBL] [Abstract][Full Text] [Related]
12. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
13. Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems.
Ghosh MK; Ghosh K; Cohen JS
Antisense Res Dev; 1992; 2(2):111-8. PubMed ID: 1327332
[TBL] [Abstract][Full Text] [Related]
14. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
15. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
Weidner DA; Busch H
Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
[TBL] [Abstract][Full Text] [Related]
16. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo.
Probst JC; Skutella T
Biochem Biophys Res Commun; 1996 Aug; 225(3):861-8. PubMed ID: 8780703
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
18. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies.
Agrawal S; Jiang Z; Zhao Q; Shaw D; Cai Q; Roskey A; Channavajjala L; Saxinger C; Zhang R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2620-5. PubMed ID: 9122245
[TBL] [Abstract][Full Text] [Related]
19. Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity.
Zon G
Toxicol Lett; 1995 Dec; 82-83():419-24. PubMed ID: 8597087
[TBL] [Abstract][Full Text] [Related]
20. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]